Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.3.5.5 (
CPS
)
1,262
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Group B Streptococcus (GBS) type III capsular polysaccharide (
CPS
III) was conjugated to recombinant cholera toxin B subunit (rCTB) using three different methods which employed (i) cystamine and N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), (ii) carbodiimide with adipic acid dihydrazide (ADH) as a spacer, or (iii) reductive amination (RA). The
CPS
III-rCTB conjugates were divided into large- and small-molecular-weight (M(r)) fractions, and the immunogenicities of the different preparations after intranasal (i.n.) immunization were studied in mice. Both large- and small-M(r) conjugates of
CPS
III-rCTB(RA) or
CPS
III-rCTB(ADH) induced high, almost comparable levels of
CPS
-specific immunoglobulin G (IgG) in serum, lungs, and
vagina
that were generally superior to those obtained with
CPS
III-rCTB(SPDP) conjugates or a
CPS
III and rCTB mixture. However, the smaller-M(r) conjugates of
CPS
III-rCTB(RA) or
CPS
III-rCTB(ADH) in most cases elicited a lower anti-
CPS
IgA immune response than the large-M(r) conjugates, and the highest anti-
CPS
IgA titers in both tissues and serum were obtained with the large-M(r)
CPS
III-rCTB(RA) conjugate. Serum IgG anti-
CPS
titers induced by the
CPS
III-rCTB(RA) conjugate had high levels of specific IgG1, IgG2a, IgG2b, and IgG3 antibodies. Based on the effectiveness of RA for coupling
CPS
III to rCTB, RA was also tested for conjugating GBS
CPS
Ia with rCTB. As for the
CPS
III-rCTB conjugates, the immunogenicity of
CPS
Ia was greatly increased by conjugation to rCTB. Intranasal immunization with a combination of
CPS
Ia-rCTB and
CPS
III-rCTB conjugates was shown to induce anti-
CPS
Ia and III immune responses in serum and lungs that were fully comparable with the responses to immunization with the monovalent
CPS
Ia-rCTB or
CPS
III-rCTB conjugates. These results suggest that the GBS
CPS
III-rCTB and
CPS
Ia-rCTB conjugates prepared by the RA method may be used in bivalent and possibly also in multivalent mucosal GBS conjugate vaccines.
...
PMID:Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. 1111 18
The effects of priming with a group B Streptococcus type III capsular polysaccharide (GBS
CPS
III)-recombinant cholera toxin B subunit (rCTB) conjugate, purified GBS
CPS
III or rCTB alone on the systemic and mucosal immune responses to
CPS
III after intranasal (i.n.) immunization were investigated in mice. Priming with purified GBS
CPS
III followed by boosting with GBS
CPS
III-rCTB conjugate or priming with the conjugate followed by boosting with free
CPS
induced comparable levels of specific IgG and IgA in both serum and in lungs and
vagina
. However, i.n. immunization comprising both priming and boosting with conjugate was superior to priming with
CPS
and boosting with conjugate or the reverse, especially with regard to inducing mucosal IgA anti-
CPS
responses. All the immunization schemes, except priming and boosting with free
CPS
, induced high and similar levels of IgG1 in serum. In contrast, mice primed with free
CPS
III and then boosted with
CPS
III-rCTB conjugate by the i.n. route failed to produce significant levels of IgG2a, IgG2b and IgG3 in serum, at difference from mice primed with the conjugate and boosted with either conjugate or free
CPS
. Pre-immunization with rCTB either i.n. or i.p. did not suppress specific serum IgG responses induced by GBS
CPS
III-rCTB conjugate intranasally, but did inhibit serum and especially mucosal IgA responses. Our findings suggest that priming with
CPS
affects the distribution of IgG subclasses to GBS
CPS
and that pre-existing anti-carrier rCTB immunity can have an inhibitory effect on mucosal immune responses elicited by the conjugate vaccine given by the i.n. route.
...
PMID:Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. 1134 99